Skip to main content
Premium Trial:

Request an Annual Quote

Amgen Invests £50M in Oxford Nanopore

NEW YORK (GenomeWeb) — Amgen will take a £50 million ($66 million) equity stake in UK-based sequencing technology firm Oxford Nanopore Technologies, the companies announced today.

Amgen will now own a roughly 3 percent stake in Oxford Nanopore, which has a valuation of approximately £1.5 billion, a spokesperson for the sequencing firm said. 

Privately owned Oxford Nanopore offers a range of tools and instruments based on a proprietary nanopore-based DNA and RNA sequencing technology. In June, the company reported a 204 percent increase in 2017 revenues to £13.8 million, with cash and cash equivalents of £57.8 million at the end of that year. It also raised £100 million in a private placement of ordinary shares in March.

The companies said that the investment aligns with Thousand Oaks, California-based Amgen's strategic focus on using human genetics to deliver new medicines to patients, and will occur through the purchase of ordinary shares at the same price-per-share as in the March financing. According to the Oxford Nanopore spokesperson, the investment is a secondary transaction in which Amgen purchased shares from other long-term shareholders.

"Oxford Nanopore's long-read sequencing capability creates a window into parts of the genome that have been out of reach, as well as giving us a much better handle on structural variants that confer risk of a wide variety of diseases," Kàri Stefànsson, founder of Amgen subsidiary DeCode Genetics, said in a statement. "We have used Oxford Nanopore technology to sequence several hundred human genomes and continue to see the promise of this emerging technology."

The Oxford Nanopore spokesperson added that there isn't a formal collaboration agreement between the firms, though DeCode presented at Oxford Nanopore's user meeting in New York at the end of last year.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.